APG101 treatment does not prevent GVT activity. (A-E) Lethally irradiated B6D2F1 mice were transplanted with B6-derived TCD BM in the presence or absence of B6-derived spleen cells (SCs) and treated with PBS starting 1 day before transplantation (day −1) or APG101 starting 1 day before (day −1) or 6 days after (day 6) transplantation. P815 mastocytoma cells were coinjected on day 0 (A-C), whereas injection of GFP-expressing B-ALL cells was performed 7 days after transplantation (D-E). P815-injected mice were analyzed for survival (A) and surviving animals/total animals treated are noted. TCD BM+SC (PBS day −1) versus TCD BM+SC (APG101 day −1) ***P < .001; versus TCD BM+SC (APG101 day 6), ***P < .001. Spleen and liver weights (B) were determined either the day mice were killed because of their moribund state or at the end of the experiment (***P < .001). Tumor manifestation was also determined by flow cytometry of liver lymphocytes. (C) FACS analysis is shown for 1 representative mouse of at least 3 mice analyzed at the end of the experiment (for mice transplanted with TCD BM plus SCs and treated with APG101) or the day mice were killed because of their moribund state (for mice transplanted with TCD BM alone or TCD BM plus SCs and treated with PBS). (D) B-ALL injected mice were analyzed for survival and surviving animals/total animals treated are indicated. TCD BM+SC (PBS day−1) versus TCD BM+SC (APG101 day −1), P = .3^ns; versus TCD BM+SC (APG101 day 6), P = .1^ns. (E) Tumor manifestation by GFP-expression in bone marrow and spleen is shown by flow cytometry for 1 representative mouse of at least 3 mice analyzed either at the end of the experiment (for mice transplanted with TCD BM plus SCs and treated with APG101) or the day mice were killed because of their moribund state (for mice transplanted with TCD BM alone or TCD BM plus SCs and treated with PBS).